Production (Stage)
Trinity Biotech plc
TRIB
$0.6341
-$0.0374-5.57%
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 18.09% | 13.99% | -14.61% | -6.54% | -28.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.09% | 13.99% | -14.61% | -6.54% | -28.63% |
| Cost of Revenue | 23.91% | 13.99% | -14.39% | -32.38% | 17.33% |
| Gross Profit | 6.79% | 14.00% | -15.03% | 1,200.91% | -96.30% |
| SG&A Expenses | 20.71% | -18.75% | -28.30% | 49.15% | -15.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | 81.69% | 100.00% | -6,900.00% | 97.67% |
| Total Operating Expenses | 33.82% | -2.37% | -18.87% | -11.00% | 6.48% |
| Operating Income | -94.43% | 58.71% | 31.96% | 22.98% | -430.49% |
| Income Before Tax | -187.17% | 62.99% | 47.23% | 34.93% | -723.74% |
| Income Tax Expenses | 19,600.00% | 50.94% | 76.92% | 11,000.00% | -99.20% |
| Earnings from Continuing Operations | -197.96% | 63.17% | 47.20% | 32.72% | -839.85% |
| Earnings from Discontinued Operations | -19,000.00% | -- | -100.90% | -100.10% | 3,696.55% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -208.22% | -12.84% | 45.42% | 24.86% | -777.14% |
| EBIT | -94.43% | 58.71% | 31.96% | 22.98% | -430.49% |
| EBITDA | -109.92% | 57.39% | 32.67% | 16.24% | -300.43% |
| EPS Basic | -78.22% | 8.72% | 44.14% | 25.30% | -471.36% |
| Normalized Basic EPS | -- | 47.17% | -- | -- | -- |
| EPS Diluted | -78.40% | 8.72% | 43.86% | 25.69% | -493.33% |
| Normalized Diluted EPS | -- | 47.17% | -- | -- | -- |
| Average Basic Shares Outstanding | 73.21% | 23.62% | 13.46% | 0.58% | 82.32% |
| Average Diluted Shares Outstanding | 73.22% | 23.62% | 13.46% | 0.58% | 74.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |